首页> 外文期刊>Analytical methods >Development and validation of a LC-MS/MS method for ivermectin quantification in dried blood spots: application to a pharmacokinetic study in Trichuris trichiura-infected adults
【24h】

Development and validation of a LC-MS/MS method for ivermectin quantification in dried blood spots: application to a pharmacokinetic study in Trichuris trichiura-infected adults

机译:LC-MS / MS方法在干血斑中伊维菌素定量的开发和验证:在Trichuris trichiura感染的成年人中进行药代动力学研究

获取原文
           

摘要

Ivermectin serves as a good addition to the small group of medications for soil-transmitted helminths, particularly against Trichuris trichiura infections. So far, ivermectin has been poorly characterized in clinical trials to treat T. trichiura; especially information on its pharmacokinetic (PK) behavior in infected populations is missing. Existing approaches to quantify ivermectin in human matrices are time-consuming, limited to matrixes of high volume and mostly do not distinguish between ivermectin and its metabolites. Thus, a sensitive, selective and rapid liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed to quantify ivermectin extracted from dried blood spots (DBS, micro-blood samples), plasma and blood. Method validation was performed on accuracy, precision, sensitivity, selectivity, linearity and stability. While the quantification of ivermectin in plasma and DBS was successfully validated, blood samples failed validation due to insufficient stability and robustness. The method was applied to samples from a clinical study with 11 adult volunteers from rural C?te d'Ivoire infected with T. trichiura sampled at 11 time points. Good agreement of the time-concentration profiles and PK parameters of plasma and DBS samples were achieved with e.g., a maximal concentration of 51.6 and 40.1 ng mL?1, respectively and identical time to reach maximal concentration of 3.9 h. Comparison of the results by Bland–Altman analysis resulted in high consistency. The less invasive and more patient-friendly DBS micro-blood sampling technique will be useful in future clinical trials to evaluate ivermectin's PK profile in larger populations.
机译:伊维菌素可作为一小部分用于土壤传播蠕虫的药物的良好补充,特别是针对Trichuris trichiura感染。到目前为止,伊维菌素在治疗Trichiura的临床试验中的特征很差。尤其是缺少有关其在感染人群中药代动力学(PK)行为的信息。现有的在人体基质中定量伊维菌素的方法非常耗时,仅限于高容量的基质,而且大多不能区分伊维菌素及其代谢物。因此,开发了一种灵敏,选择性和快速的液相色谱-串联质谱(LC-MS / MS)方法来定量从干血斑(DBS,微血样品),血浆和血液中提取的伊维菌素。在准确性,精密度,灵敏度,选择性,线性和稳定性方面进行了方法验证。尽管成功验证了血浆和DBS中伊维菌素的定量,但由于稳定性和鲁棒性不足,血液样本未能通过验证。该方法已应用于一项临床研究的样本,该样本是在11个时间点对来自农村科特迪瓦的成年志愿者感染的Trichiura毛癣菌进行采样的11名样本。血浆和DBS样品的时间浓度曲线和PK参数的一致性很好,例如最大浓度分别为51.6和40.1 ng mL?1,达到最高浓度3.9 h的时间相同。通过Bland–Altman分析对结果进行比较,结果具有很高的一致性。侵入性较小且对患者更友好的DBS微血采样技术将在将来的临床试验中用于评估伊维菌素在较大人群中的PK状况。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号